Abstract
Purpose
Ciliopathies are highly heterogeneous clinical disorders of the primary cilium. We aim to characterize a large cohort of ciliopathies phenotypically and molecularly.
Methods
Detailed phenotypic and genomic analysis of patients with ciliopathies, and functional characterization of novel candidate genes.
Results
In this study, we describe 125 families with ciliopathies and show that deleterious variants in previously reported genes, including cryptic splicing variants, account for 87% of cases. Additionally, we further support a number of previously reported candidate genes (BBIP1, MAPKBP1, PDE6D, and WDPCP), and propose nine novel candidate genes (CCDC67, CCDC96, CCDC172, CEP295, FAM166B, LRRC34, TMEM17, TTC6, and TTC23), three of which (LRRC34, TTC6, and TTC23) are supported by functional assays that we performed on available patient-derived fibroblasts. From a phenotypic perspective, we expand the phenomenon of allelism that characterizes ciliopathies by describing novel associations including WDR19-related Stargardt disease and SCLT1- and CEP164-related Bardet–Biedl syndrome.
Conclusion
In this cohort of phenotypically and molecularly characterized ciliopathies, we draw important lessons that inform the clinical management and the diagnostics of this class of disorders as well as their basic biology.
INTRODUCTION
In humans, the centrioles of postmitotic cells reorganize microtubules to seed the outgrowth of antenna-like structures known as the cilia, abnormalities of which manifest in a wide range of clinical presentations depending on the type of cilia that are affected. Cilia are classified on the basis of three fundamental features: number (mono vs. multi), motility (motile vs. immotile), and ultrastructure arrangement of axoneme, specifically the presence or lack of two central microtubule singlets (9 + 2 vs. 9 + 0, respectively).
1.- Bernabé-Rubio M.
- Alonso M.A.
Routes and machinery of primary cilium biogenesis.
The term “ciliopathies” is usually reserved for clinical disorders of the primary cilium, an immotile 9 + 0 monocilium, with or without involvement of the motile 9 + 0 monocilium of the embryonic node, whereas clinical disorders of the motile 9 + 2 cilia are usually referred to as primary ciliary dyskinesia.
2.- Kempeneers C.
- Chilvers M.A.
To beat, or not to beat, that is question! The spectrum of ciliopathies.
The past two decades have witnessed vast changes in our understanding of the clinical and molecular aspects of ciliopathies, a trend that has only accelerated over the past decade with the advent of next-generation sequencing. Several themes have emerged from these studies. For example, the ubiquitous distribution of the primary cilium is consistent with the observation that no organ system is spared in ciliopathies, although different ciliopathies have variable tissue and organ predilection.
3.- Braun D.A.
- Hildebrandt F.
Ciliopathies.
This can be seen in the conspicuous central nervous system (CNS) involvement in Joubert syndrome (characteristic posterior fossa malformation known as molar tooth sign), acrocallosal syndrome (strong predilection to hydrocephalus and agenesis of corpus callosum), and Meckel–Gruber syndrome (strong predilection to neural tube defect in the form of occipital encephalocele) as part of their multisystemic nature. Similarly, the multisystem phenotype of Bardet–Biedl syndrome has a strong predilection to eye involvement (retinitis pigmentosa), nephronophthisis to kidneys (cysts formation), oral–facial–digital to oral cavity (cleft and hamartoma), and cranioectodermal dysplasia to skeleton (skeletal dysplasia and craniosynostosis). It has also become clear that the delineation of specific ciliopathy syndromes overlooks the remarkable variability of phenotypic presentation that often blurs the clinical boundaries between these syndromes or highlights their allelism.
4.- Shaheen R.
- Szymanska K.
- Basu B.
- et al.
Characterizing the morbid genome of ciliopathies.
Lastly, earlier speculations about the non-Mendelian inheritance of these disorders have given way to the rigorous analysis of the role of modifiers of disease severity within the widely accepted context of Mendelian inheritance of these disorders.
4.- Shaheen R.
- Szymanska K.
- Basu B.
- et al.
Characterizing the morbid genome of ciliopathies.
, 5.- Phelps I.G.
- Dempsey J.C.
- Grout M.E.
- et al.
Interpreting the clinical significance of combined variants in multiple recessive disease genes: systematic investigation of Joubert syndrome yields little support for oligogenicity.
, 6.- Abu-Safieh L.
- Al-Anazi S.
- Al-Abdi L.
- et al.
In search of triallelism in Bardet–Biedl syndrome.
Despite this progress, our knowledge of ciliopathies is far from complete. New clinical phenotypes are still being described and are shedding new light on the role of the primary cilium in the development and function of the human body. Thus, there remains a need to define the clinical manifestations of abnormal primary cilia, not only through the study of patients with “compatible” phenotypes, but also through the reverse phenotyping of those who are found to have deleterious variants in established ciliopathy genes. This also highlights the need to accelerate the discovery of clinically relevant members of the “ciliome,” i.e., genes that encode proteins with ciliary function. We have recently estimated the contribution of “known” genes to >85% of all cases with ciliopathies.
4.- Shaheen R.
- Szymanska K.
- Basu B.
- et al.
Characterizing the morbid genome of ciliopathies.
Although this suggests that the overwhelming majority of patients with ciliopathies should be able to receive a genetic diagnosis, it also shows that disease gene discovery should continue to serve the unmet needs of a significant minority of patients.
In this study, we attempt to address the above research questions by describing the clinical and molecular findings in a large cohort of 125 families. These families include 12 who were labeled “negative” in the previous cohort to provide updates on their genetic diagnosis. These also include 51 families who underwent a “genomics-first” analysis of various clinical phenotypes (regardless of their compatibility with ciliopathies) and were found to have deleterious variants in known ciliopathy genes.
MATERIALS AND METHODS
Human subjects
Two types of patients were eligible for enrollment in this study. First, we included all cases whose phenotype was consistent with any of the established ciliopathies syndromes. Second, we included all cases with biallelic pathogenic/likely pathogenic variants in established ciliopathies genes from a large cohort of patients who underwent exome sequencing (ES).
7.- Monies D.
- Abouelhoda M.
- Assoum M.
- et al.
Lessons learned from large-scale, first-tier clinical exome sequencing in a highly consanguineous population.
Informed consent was obtained from all subjects, as was permission to publish photos and the study was approved by the local institutional review board (IRB) (King Faisal Specialist Hospital and Research Centre Research Advisory Council [KFSRHC RAC] #2070023, 2080006, and 2121053). Referring physicians were asked to fill out a standard data collection form as described previously.
4.- Shaheen R.
- Szymanska K.
- Basu B.
- et al.
Characterizing the morbid genome of ciliopathies.
Other family members were recruited whenever possible with informed consent to verify the segregation of the variants.
Next-generation sequencing and variant interpretation
The technical details of ES are described elsewhere.
4.- Shaheen R.
- Szymanska K.
- Basu B.
- et al.
Characterizing the morbid genome of ciliopathies.
Variants were classified according to the American College of Medical Genetics and Genomics (ACMG) guidelines.
8.- Richards S.
- Aziz N.
- Bale S.
- et al.
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Consistent with the guidelines, variants in genes we propose as novel candidates are classified as variants of unknown significance (VUS) regardless of their supporting level of evidence (see below). Importantly, each exome was fully analyzed for additional variants of potential relevance to the phenotype even when a likely causal biallelic variant is identified.
Functional characterization of cilia
Fibroblasts derived from punch skin biopsies obtained from affected and control individuals were propagated in RPMI media (Thermo Fisher Scientific, 22400–089) supplemented with 15% v/v heat inactivated fetal bovine serum (Thermo Fisher, cat. number 16140071), 1% v/v L-glutamine, and 1% v/v penicillin and streptomycin and incubated in a humidified, 5% CO2 atmosphere at 37 °C.
For immunostaining, fibroblasts were grown to 85% confluence, cells were fixed with 3.6% formaldehyde, permeabilized in 0.1% 100× Tritonx (T9284, Sigma), and blocked in 1% bovine serum albumin. The following primary and their compatible secondary antibodies (TTC6 antibody PA5–64406, Thermo Fisher; TTC23 antibody PA5–58937 and LRRC34 antibodies NBP1–81146, Novus Biologicals) were used to test the localization of the protein in control and patient fibroblasts.
For ciliogenesis potential and to assess ciliary length, patient and control fibroblasts were cultured to 85% confluence on a coverslip, starved for 48 hours in Opti-MEM™ (Thermo Fisher), and then used for immunostaining with acetylated ɑ-tubulin antibody T7451 (Sigma-Aldrich) and DAPI.
For sonic hedgehog (SHH) signaling comparison, sets of affected and control fibroblasts were treated with either smoothened agonist (SAG) at 100 nM or DMSO for 18–21 hours. GLI1 was used as readout for SHH signaling on quantitative reverse transcription polymerase chain reaction (PCR). The experiment was run in triplicates on serum-starved cells.
DISCUSSION
Ciliopathies are important Mendelian disorders that involve nearly every organ system. This study is an attempt to further define the phenotypic and variant spectrum of ciliopathies by exploiting the highly consanguineous nature of the Saudi population, which not only facilitates the occurrence of these recessive disorders but also their mapping to the underlying variant through autozygome analysis. The latter was key to the identification of cryptic splicing variants that defied detection by standard clinical testing.
An advantage of conducting comprehensive genomic analysis of large cohorts of patients with a wide phenotypic spectrum is the achievement of unbiased links between variants and phenotypes. This is particularly relevant in the highly heterogeneous field of ciliopathies since these disorders do not always conform to predefined clinical categories and are characterized by a high degree of allelism. Indeed, our study expands the phenotypic expression of many ciliopathies genes. One noteworthy example is our finding that homozygosity for
PKD1 pathogenic variants can cause a severe ciliopathy phenotype resembling MKS, a reminder of the unexpected phenotypic consequences of homozygous variants in genes that are typically linked to dominant diseases.
31.- Monies D.
- Maddirevula S.
- Kurdi W.
- et al.
Autozygosity reveals recessive mutations and novel mechanisms in dominant genes: implications in variant interpretation.
Although PKD1 ciliary localization is well established, its exact function remains unknown. Our finding that biallelic
PKD1 variant results in brain anomalies consistent with a ciliopathies spectrum seems to confirm the previously described mouse phenotype.
32.- Kurbegovic A.
- Côté O.
- Couillard M.
- Ward C.J.
- Harris P.C.
- Trudel M.
Pkd1 transgenic mice: adult model of polycystic kidney disease with extrarenal and renal phenotypes.
Posterior fossa involvement and short bones were also described very recently by Al-Hamed et al. in patients with biallelic
PKD1 variant.
33.- Al-Hamed M.H.
- Alsahan N.
- Rice S.J.
- et al.
Bialleleic PKD1 mutations underlie early-onset autosomal dominant polycystic kidney disease in Saudi Arabian families.
Other examples include
INVS-related severe liver disease,
NPHP3- and
TTC21B-related renal agenesis,
WDR19-related nonsyndromic Stargardt disease, and
SCLT1- and
CEP164-related BBS. We also note the unusual observation of macrocephalic overgrowth in several children with BBS. Although accelerated linear growth is not an unusual co-occurrence with childhood obesity, this is not typically the case in BBS patients. It is interesting that although macrocephaly was observed in ~11% of the first reported nationwide BBS cohort,
34.The syndrome of Laurence-Moon-Bardet-Biedl and allied diseases in Switzerland: clinical, genetic and epidemiological studies.
this feature is rarely mentioned in subsequent BBS cohorts, and we are aware of a single report of a BBS patient who is macrocephalic and with a height and weight on the 95th centile.
35.Patient with Bardet–Biedl syndrome presenting with nystagmus at fifteen months of age.
The very high percentage of ciliopathies patients with biallelic candidate variants in our cohort shows that the non-Mendelian model need not be invoked in the overwhelming majority of cases. Furthermore, despite their highly variable expressivity, we found no instances of nonpenetrance for any of the variants we report in this cohort. The family (14DG0045) with a deep intronic
SDCCAG8 variant (NM_006642.2:c.741–152G > A) is illustrative in this regard. This family of two siblings with BBS was reported negative by clinical ES. However, subsequent autozygome mapping highlighted
SDCCAG8 as a likely candidate to be further interrogated by RT-PCR, which did reveal aberrant splicing (r.740_741ins741-202_741-1, p.Arg247Serfs*23) that eventually led to the identification of the deep intronic variant. While this variant was homozygous in the two affected siblings, it was also homozygous in the 3-year-old younger sister who is said to be normal. However, subsequent electroretinograph (ERG) confirmed that she has early stages of retinitis pigmentosa. Thus, it is critical to fully investigate patients with deleterious biallelic variants in ciliopathies genes to avoid the erroneous conclusion of nonpenetrance. Another illustrative example is the BBS patient 17DG0753 in whom clinical ES suggested the possibility of a non-Mendelian inheritance based on double heterozygosity for a truncating
BBS7 variant (NM_018190:c.1471_1472del:p.[Leu491Phefs*10]) and
INVS:NM_014425:exon6:c.643A > G:p.N215D. Again, RT-PCR analysis of
BBS7 revealed that this patient was in fact compound heterozygous for another variant in
BBS7 as revealed by the apparent homozygosity of the heterozygous variant on RT-PCR tracing (Fig.
S5). Indeed, this is a reminder that given the tremendous genetic heterogeneity of ciliopathies, it is not uncommon to identify heterozygosity for deleterious variants in ciliopathies genes other than the causal one and these should not be mistaken for non-Mendelian inheritance. We and others have previously shown that patients with ciliopathies do not have a higher burden of deleterious variants in ciliopathies genes (beyond their causal variants in single genes) compared with other patients, and that “unsolved” cases are unlikely solved using the non-Mendelian model using a rigorous statistical approach.
4.- Shaheen R.
- Szymanska K.
- Basu B.
- et al.
Characterizing the morbid genome of ciliopathies.
,5.- Phelps I.G.
- Dempsey J.C.
- Grout M.E.
- et al.
Interpreting the clinical significance of combined variants in multiple recessive disease genes: systematic investigation of Joubert syndrome yields little support for oligogenicity.
None of the novel candidate genes we report in this cohort were found to be mutated in more than one family. This should not be surprising since virtually all recently published disease genes account for an increasingly small percentage of the morbid genome of ciliopathies, such that much larger cohorts are needed than the one described by this study to identify multiple hits. A practical alternative is to share candidate genes with reasonable level of evidence to allow postpublication matchmaking. In the case of the three novel genes for which patient fibroblasts are available to directly demonstrate (1) the ciliary nature of the genes and (2) the abnormal localization of the mutated protein and (3) associated abnormal ciliary structure and/or function, we believe a reasonable case is made for their candidacy especially when one considers the homozygous truncating nature of the variants identified in each of these genes. However, we note that the lower confidence candidate genes we report are also worth pursuing in other ciliopathies cohorts given their established link to ciliary biology and the mostly truncating nature of the variants identified therein.
In summary, we report a large cohort of ciliopathies from which we draw important phenotypic observations concerning the variable presentation of these disorders and their allelism. We also show the potential for a high diagnostic rate based on previously reported genes especially when employing an approach that takes into account the preponderance of noncanonical splicing variants in these genes. Finally, we support the candidacy of a number of previously reported genes and propose the candidacy of additional genes that should be investigated in future studies.
Article info
Publication history
Accepted:
January 29,
2020
Received:
November 1,
2019
Copyright
© 2020, The Author(s), under exclusive licence to the American College of Medical Genetics and Genomics